Antibody Discovery

Antibody Discovery Services and Platforms Market (4th Edition): Distribution by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), Antibody Discovery Method (Library based, Hybridoma based, Single Cell based, Transgenic Animal based), Nature of Antibody Generated (Humanized, Human, Chimeric, Murine) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    March 2022

  • Pages
    536

  • View Count
    27887

  • Buy Now

Example Insights

Antibody-Discovery-Services-Context Antibody-Discovery-Services-Platforms Antibody-Discovery-Services-List Antibody-Discovery-Services-Distribution-by-Year Antibody-Discovery-Services-Portfolio-Competitiveness-Analysis
Antibody-Discovery-Services-List-of-Platform-Providers Antibody-Discovery-Services-Distribution Antibody-Discovery-Services-Technology-Competitiveness-Analysis Antibody-Discovery-Services-Partnerships-and-Collaborations Antibody-Discovery-Services-Funding-and-Investments
Antibody-Discovery-Services-Deal-Structures Antibody-Discovery-Services-Opportunity-Analysis Antibody-Discovery-Services-Geographical-Region    

Overview

Since the approval of Orthoclone OKT3, a murine monoclonal antibody against T cell expressed CD3 (for the treatment of acute transplant rejection) in 1986, antibody therapeutics have evolved into a prominent class of therapeutics. These therapeutics have high target specificities and favorable safety profiles. Currently, close to 100 monoclonal antibodies have been approved while more than 500 molecules are being evaluated in clinical trials. Some of the recently approved monoclonal antibody therapies include (in reverse chronological order) Tivdak® (September 2021), Saphnelo® (August 2021), Rybrevant® (May 2021), Ebanga (December 2020) and MARGENZA® (December 2020). The growing popularity of antibody based therapeutics is also reflected from the extensive research being conducted on other novel antibody formats, such as bispecific antibodies, antibody drug conjugates (ADCs) and antibody fragments in the past few years.

It is worth highlighting that the process of antibody development, beginning from the discovery to the commercialization of a clinically validated product, takes around 10-15 years. Moreover, antibody discovery and clinical research are capital intensive processes, which, on an average, require investments of around USD 4-10 billion. Further, it is a well-known fact that only a small proportion of lead molecules that are shortlisted for further investigation during the discovery phase make it into the clinical phase, and an even lesser number of product candidates enter the market. In order to optimize on internal resource utilization and save costs, pharmaceutical companies are increasingly outsourcing various aspects of their discovery-stage operations to specialty contract research organizations (CROs). Apart from being considered a viable business strategy, engaging third party service providers offers both time and cost related benefits to the drug / therapy developers. Given the rising demand for antibody based therapeutics and growing preference for outsourcing, we are led to believe that the opportunity for contract service provides and technology developers is likely to increase at a steady rate in the foreseen future.

Scope of the Report

The “Antibody Discovery Services and Platforms Market by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), Antibody Discovery Method (Library based, Hybridoma based, Single Cell based, Transgenic Animal based), Nature of Antibody Generated (Monoclonal, Bispecific, Antibody-Drug Conjugates, Antibody Fragments) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecast (4th Edition), 2021-2035” report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution in this industry over the next ten years. The study underlines an in-depth analysis of the antibody discovery technologies and services that assist in the development of antibody therapeutics. In addition to other elements, it includes:

  • An overview of the overall landscape of antibody discovery service providers along with the information on a number of parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic). 
  • An insightful competitiveness analysis of antibody discovery service providers, based on supplier strength (based on a company’s employee count and years of experience) and service portfolio specifications, such as number of antibody discovery services offered, number of antibody discovery methods adopted, and number of subject specific agreements signed.
  • Elaborate profiles of antibody discovery service providers. Each company profile features a brief overview of the company, its financial information (if available), antibody discovery service portfolios and an informed future outlook. 
  • A detailed review of the overall landscape of antibody discovery platforms, along with the information on the technology developers such as year of establishment, company size, location of headquarters and type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others). In addition, the chapter highlights an in-depth analysis of antibody discovery platforms based on type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others) and availability of intellectual property.
  • A detailed competitiveness analysis of antibody discovery platforms, taking into consideration the supplier power (based on the year of establishment of developer) and key technology specifications, such as type of antibody discovered, compatibility of antibodies in human (fully human or not), availability of patent protection, number of deals signed for a particular platform between 2015 and 2021.  
  • Elaborate profiles of antibody discovery platform providers. Each company profile features a brief overview of the company, its financial information (if available), details on antibody discovery technology / platform(s) offered and an informed future outlook.
  • An assessment of antibody discovery service and platform providers’ capability in different regions, based on a number of relevant parameters. For platform providers, these parameters include number of technologies offered, number of antibody discovery methods employed, and type of antibody discovered. On the other hand, the service providers have been evaluated based on the type(s) of service offered.
  • An analysis of the partnerships that have been established in this domain since 2015, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, clinical trial agreements, and other relevant deals.
  • An analysis of the investments made in this domain, during the period between 2016 and 2021, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, in companies that are engaged in the field of antibody drug discovery. 
  • Detailed profiles on the top five therapeutic antibody products, which have generated the highest revenues. Each profile features a brief overview of the drug, the type of antibody discovery method it employs and the annual historical sales of the product.
  • A case study on antibody humanization and affinity maturation, including a list of players that are presently offering such services and platforms, a publication analysis highlighting the research trends in this field and a detailed discussion on other affiliated trends, key drivers and challenges, under a comprehensive SWOT framework.
  • A brief discussion on the imminent opportunities (such as novel antibody therapeutics, innovative technologies and other future opportunities) in the field of drug discovery that are likely to impact the future evolution of this market over the coming years.
  • An analysis of the deal structure, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.

One of the key objectives of the report was to estimate the existing market size and potential future opportunities for antibody discovery platforms and services, for the next decade. Based on parameters, such as the overall R&D expenditure available to CROs, percentage of R&D expenses incurred in each discovery step, and outsourcing profile, we have provided an informed estimate of the likely evolution of the antibody discovery services market in the mid to long term, for the time period 2021-2035. The report also features the likely distribution of the current and forecasted opportunity within antibody discovery services market across [A] the various steps involved in antibody discovery process (antigen designing, hit generation, lead selection, lead optimization and lead characterization), [B] antibody discovery methods (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), [C] the nature of antibody generated (whether human/ fully human or not) and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). In addition, for estimating the future market opportunities for platform providers, we have considered the likely licensing deal structures and agreements that are expected to be inked in the foreseen future. The future opportunities within the antibody discovery platforms market has been segmented across key geographical regions (North America, Europe and Asia- Pacific). The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Tracey Mullen (Chief Executive Officer, Abveris Antibody)
  • Lisa Delouise (Founder and Chief Technology Officer, Nidus Biosciences)
  • Mark Kubik (Chief Business Officer, AvantGen)
  • Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology)
  • Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio)
  • Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera)
  • Sanjiban K Banerjee (Director, AbGenics Life Sciences)
  • Ignacio Pino (Chief Executive Officer and President, CDI Laboratories) 
  • Jeng Her (Chief Executive Officer, AP Biosciences) 
  • Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB)
  • Debra Valsamis (Business Development Associate, Antibody Solutions)
  • Christel Iffland (Vice President, Ligand Pharmaceuticals)
  • Aaron Sato (former Chief Scientific Officer, LakePharma)

All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry players involved in offering services and technologies related to antibody discovery?
  • What is the relative competitiveness of the players offering services related to antibody discovery, based across different geographies?
  • What tis the relative competitiveness of the technologies pertaining to antibody discovery across different peer groups?
  • Which partnership models are commonly adopted by industry stakeholders offering services and technologies related to antibody discovery? 
  • What is the trend for capital investments in the antibody discovery services and platforms market?
  • How is the current and future market opportunity related to antibody discovery services an platforms, likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It presents a high-level view on the current scenario within the antibody discovery services and platform market and its evolution in the short-mid-term and long term.

Chapter 3 provides a general introduction of antibodies featuring details on their historical background, structure, isotypes, mechanism of action and applications. It also emphasizes on the different types of antibodies, namely monoclonal, bispecific and polyclonal antibodies.

Chapter 4 features a detailed overview on the antibody discovery process and the various methods used in the discovery of these therapeutic biomolecules. It also highlights a comparison of different antibody discovery methods that are currently available. Additionally, the chapter provides insights on the gradual shift in development trends of monoclonal antibodies over the last three decades, tracking the transition from fully murine to fully human product variants.

Chapter 5 provides a general overview of the current market landscape of more than 80 service providers that are currently active in this domain. It features a detailed analysis of these players based on several parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic).

Chapter 6 provides an insightful competitiveness analysis of antibody discovery service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (based on the year of establishment of the service provider) and service strength (which takes into account the number of antibody discovery services offered, number of antibody discovery methods adopted, and number of subject specific agreements signed).

Chapter 7 provides detailed profiles of the stakeholders that are actively engaged in providing antibody discovery services to biopharmaceutical companies. Each company profile includes a brief overview of the company, its financial information (if available), details on antibody discovery services, recent developments and an informed future outlook.

Chapter 8 presents the current market landscape of over 120+ antibody discovery platform providers, including information on their company details such as year of establishment, company size, location of headquarters and type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others). In addition, the chapter highlights an in-depth analysis of 170+ antibody discovery platforms based on type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others) and availability of intellectual property.

Chapter 9 provides an insightful competitiveness analysis of antibody discovery platforms. It highlights the leading players in this domain, taking into consideration the supplier power (based on the year of establishment of the platform provider) and key specifications of the platforms, such as type of antibody discovered, compatibility of antibodies in human (fully human or not), availability of patent protection, number of deals signed for a particular platform (2015-2021).  

Chapter 10 provides detailed profiles of the stakeholders, which actively provide access / licenses to their antibody discovery technology / platforms to other companies. Each company profile includes a brief overview of the company, its financial information (if available), details on antibody discovery technology / platforms, recent developments and an informed future outlook

Chapter 11 presents the antibody discovery capabilities in different regions, based on a number of relevant parameters, such as type of service offered for service providers, and number of technologies offered, number of antibody discovery methods and type of antibody discovered for platform providers.

Chapter 12 features an in-depth analysis and discussion on the various partnerships that have been inked between the players in this market in the time period between 2015 and 2021 (till November). It includes a brief description of partnership models (such as acquisitions, product development agreements, product integration agreements, commercialization agreements, clinical trial agreements, licensing agreements, manufacturing agreements, and service agreements) adopted by the stakeholders.

Chapter 13 presents an analysis of the investments made in this domain during the period 2016-2021 (till November), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of discovery in companies that are focused on antibody discovery.

Chapter 14 features an insightful market forecast analysis, highlighting the likely growth of antibody discovery services domain till the year 2035. In order to provide details on the future opportunities, our projections have been segmented on the basis of  [A] the various steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), [B] antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), [C] the nature of antibody generated (whether human/ fully human or not) and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). 

Chapter 15 presents the likely growth of antibody discovery platform market, on the basis of licensing deal structures and agreements signed or planned in the foreseen future. In order to provide details on the future opportunities, the projections have been segmented on the basis of 
key geographical regions (North America, Europe and Asia- Pacific).

Chapter 16 provides deal structure analysis, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.

Chapter 17 features detailed profiles of the most successful therapeutic monoclonal antibody products (as per sales reported in 2020). It provides information on top five drugs, namely Humira®, Keytruda®, Stelara®, Opdivo® and Avastin®, their historical sales, and discovery process and methods.
    
Chapter 18 features a case study on antibody humanization and affinity maturation, highlighting the importance of these methods in the process of antibody discovery and development. The chapter presents a list of key players along with the information on their respective location, their expertise across antibody humanization and / or affinity maturation, the methodology adopted for providing such services and the revenue / business models adopted by the players involved in this domain. In addition, chapter provides insights on a publication analysis representing the recent trends in research on antibody humanization across various academic institutes, highlighting the ongoing innovation in this domain. Further, the report features a detailed SWOT analysis, which elaborates on the various drivers and challenges that are likely to influence the activities of players engaged in this domain.

Chapter 19 provides an overview of future growth opportunities in the field of antibody discovery. The chapter discusses the upcoming antibody therapeutics and technologies, which are being developed / adopted by the antibody drug discovery service and platform providers that are likely to have influence on the industry’s evolution over the coming decade.

Chapter 20 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (in alphabetical order of person name) Tracey Mullen (Chief Executive Officer, Abveris Antibody), Lisa Delouise (Founder and Chief Technology Officer, Nidus Biosciences), Mark Kubik (Chief Business Officer, AvantGen), Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology), Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio), Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera), Sanjiban K Banerjee (Director, AbGenics Life Sciences), Ignacio Pino (Chief Executive Officer and President, CDI Laboratories), Jeng Her (Chief Executive Officer, AP Biosciences), Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB), Debra Valsamis (Business Development Associate, Antibody Solutions),  Christel Iffland (Vice President, Ligand Pharmaceuticals), Aaron Sato (Chief Scientific Officer, LakePharma / Twist Biosciences)

Chapter 21 summarizes the entire report, highlighting the various facts related to contemporary market trend and the likely evolution of the antibody discovery service and platform market.

Chapter 22 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 23 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION 
3.1. Chapter Overview
3.2. Structure of Antibodies
3.3. History of Antibody Development
3.4. Antibody Isotypes
3.5. Mechanism of Action of Antibodies 
3.6. Classification of Antibodies
3.6.1. Monoclonal Antibodies
3.6.2. Polyclonal Antibodies
3.6.3. Bispecific Antibodies
3.7. Applications of Antibodies
3.8. Concluding Remarks

4. ANTIBODY DISCOVERY PROCESS AND METHODS
4.1. Chapter Overview
4.2. Antibody Discovery Process
4.2.1. Target Selection and Validation
4.2.2. Hit Generation
4.2.3. Lead Selection
4.2.4. Lead Optimization
4.2.4.1. Humanization
4.2.4.2. Affinity Maturation
4.2.4.3. Fc Engineering
4.2.5. Lead Characterization
4.2.6. Candidate Selection

4.3. Antibody Discovery Methods
4.3.1. Hybridoma Technology-Based Method
4.3.2. In vitro Display Method
4.3.2.1. Phage Display
4.3.2.2. Yeast Display
4.3.2.3. Ribosomal Display
4.3.3. Transgenic Animal-Based Method
4.3.4. Single B Cell-Based Method
4.3.5. Advantages and Disadvantages of Existing Antibody Discovery Techniques

4.4. Evolution of Monoclonal Antibodies
4.4.1. Fully Human Monoclonal Antibodies

5. ANTIBODY DISCOVERY SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Antibody Discovery Service Providers: List of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Service Offered
5.2.5. Analysis by Company Size and Type of Service Offered
5.2.6. Analysis by Type of Antibody Discovery Method
5.2.7. Grid Representation: Analysis by Type of Antibody Discovery Method, Type of Antibody Discovered and Location of Headquarters
5.2.8. Analysis by Animal Model Used
5.2.9. Analysis by Type of Antibody Discovered
5.2.10. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered
5.2.11. Analysis by Purpose of Antibody Discovery

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Key Parameters
6.4. Competitiveness Analysis: Antibody Discovery Service Providers
6.4.1. Antibody Discovery Service Providers based in North America
6.4.2. Antibody Discovery Service Providers based in Europe
6.4.3. Antibody Discovery Service Providers based in Asia-Pacific

7. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers in North America
7.2.1. Abwiz Bio
7.2.1.1. Company Overview
7.2.1.2. Antibody Discovery Services Portfolio
7.2.1.3. Recent Developments and Future Outlook

7.2.2. Aragen Bioscience (a GVK BIO company)
7.2.2.1. Company Overview
7.2.2.2. Antibody Discovery Services Portfolio
7.2.2.3. Recent Developments and Future Outlook

7.2.3. Creative Biolabs
7.2.3.1. Company Overview
7.2.3.2. Antibody Discovery Services Portfolio
7.2.3.3. Recent Developments and Future Outlook

7.2.4. Distributed Bio
7.2.4.1. Company Overview
7.2.4.2. Antibody Discovery Services Portfolio
7.2.4.3. Recent Developments and Future Outlook

7.2.5. ImmunoPrecise Antibodies
7.2.5.1. Company Overview
7.2.5.2. Financial Information
7.2.5.3. Antibody Discovery Services Portfolio
7.2.5.4. Recent Developments and Future Outlook

7.2.6. Integral Molecular
7.2.6.1. Company Overview
7.2.6.2. Antibody Discovery Services Portfolio
7.2.6.3. Recent Developments and Future Outlook

7.2.7. LakePharma
7.2.7.1. Company Overview
7.2.7.2. Antibody Discovery Services Portfolio
7.2.7.3. Recent Developments and Future Outlook

7.2.8. Syd Labs
7.2.8.1. Company Overview
7.2.8.2. Antibody Discovery Services Portfolio

7.3. Antibody Discovery Service Providers in Europe
7.3.1. Abzena
7.3.1.1. Company Overview
7.3.1.2. Financial Information
7.3.1.3. Antibody Discovery Services Portfolio
7.3.1.4. Recent Developments and Future Outlook

7.3.2. BIOTEM
7.3.2.1. Company Overview
7.3.2.2. Antibody Discovery Services Portfolio
7.3.2.3. Recent Developments and Future Outlook

7.3.3. PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group)
7.3.3.1. Company Overview
7.3.3.2. Antibody Discovery Services Portfolio
7.3.3.3. Recent Developments and Future Outlook

7.4. Antibody Discovery Service Providers in Asia-Pacific
7.4.1. ChemPartner
7.4.1.1. Company Overview
7.4.1.2. Antibody Discovery Services Portfolio
7.4.1.3. Recent Developments and Future Outlook

7.4.2. HD Biosciences
7.4.2.1. Company Overview
7.4.2.2. Antibody Discovery Services Portfolio

7.4.3. Viva Biotech
7.4.3.1. Company Overview
7.4.3.2. Financial Information
7.4.3.3. Antibody Discovery Services Portfolio
7.4.3.4. Recent Developments and Future Outlook

7.4.4. WuXi Biologics
7.4.4.1. Company Overview
7.4.4.2. Financial Information
7.4.4.3. Antibody Discovery Services Portfolio
7.4.4.4. Recent Developments and Future Outlook

8. ANTIBODY DISCOVERY TECHNOLOGIES: CURRENT MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Antibody Discovery Platform Providers: List of Industry Players
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size 
8.2.3. Analysis by Location of Headquarters
8.2.4. Analysis by Type of Antibody Discovered
8.3. Antibody Discovery: List of Technologies and Platforms
8.3.1. Analysis by Type of Antibody Discovery Method
8.3.2. Analysis by Type of Antibody Discovery Method and Location of Headquarters
8.3.3. Analysis by Animal Model Used
8.3.4. Analysis by Patent Availability

9. TECHNOLOGY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Methodology
9.3. Library based Antibody Discovery Platforms
9.3.1. Key Assumptions and Parameters
9.3.2. Technology Competitiveness Analysis
9.4. Single Cell based Antibody Discovery Platforms 
9.4.1 Key Assumptions and Parameters

9.4.2. Technology Competitiveness Analysis 
9.5. Transgenic Animal based Antibody Discovery Platforms
9.5.1. Key Assumptions and Parameters
9.5.2. Technology Competitiveness Analysis
9.6. Hybridoma based Antibody Discovery Platforms
9.6.1. Key Assumptions and Parameters
9.6.2. Technology Competitiveness Analysis
9.7. Other Antibody Discovery Platforms 
9.7.1. Key Assumptions and Parameters
9.7.2. Technology Competitiveness Analysis 

10. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
10.1. Chapter Overview
10.2. Harbour BioMed
10.2.1. Company Overview
10.2.2.  Antibody Discovery Platforms Portfolio
10.2.2.1. H2L2 Platform
10.2.2.2. HCAb Platform
10.2.3. Recent Developments and Future Outlook 

10.3. ImmunoPrecise Antibodies
10.3.1. Company Overview
10.3.2. Financial Information
10.3.3. Antibody Discovery Platforms Portfolio 
10.3.3.1. Abthena™
10.3.3.2. B cell Select™
10.3.3.3. DeepDisplay™
10.3.3.4. ModiFuse™
10.3.3.5. ModiPhage™
10.3.3.6. ModiSelect™
10.3.3.7. ModiTune™
10.3.4. Recent Developments and Future Outlook

10.4. Kymab
10.4.1. Company Overview
10.4.2. Antibody Discovery Platforms Portfolio 
10.4.2.1. Kymouse™
10.4.2.2. IntelliSelect®
10.4.3. Recent Developments and Future Outlook

10.5. Ligand Pharmaceuticals
10.5.1. Company Overview
10.5.2. Financial Information
10.5.3. Antibody Discovery Platforms Portfolio 
10.5.3.1. OmniAb®
10.5.3.1.1. OmniChicken®
10.5.3.1.2. OmniClic™
10.5.3.1.3. OmniFlic®
10.5.3.1.4. OmniMouse®
10.5.3.1.5. OmniRat®
10.5.4. Recent Developments and Future Outlook

10.6. MorphoSys
10.6.1. Company Overview
10.6.2. Financial Information
10.6.3. Antibody Discovery Platforms Portfolio 
10.6.3.1. arYla® Technology
10.6.3.2. HuCAL® Technology
10.6.3.3. Ylanthia® Technology
10.6.4. Recent Developments and Future Outlook

11. REGIONAL CAPABILITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Regional Capability Analysis: Antibody Discovery Service Providers
11.3.1 Regional Capability Analysis: Antibody Discovery Service Providers in North America
11.3.2. Regional Capability Analysis: Antibody Discovery Service Providers in Europe
11.3.3. Regional Capability Analysis: Antibody Discovery Service Providers in Asia-Pacific
 
11.4. Regional Capability Analysis: Antibody Discovery Platform Providers
11.4.1. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers in North America
11.4.2. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers in Europe
11.4.3. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers in Asia-Pacific

11.5. Concluding Remarks

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. List of Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Type of Company (Service / Platform Providers)
12.3.4. Analysis by Type of Antibody Discovered
12.3.5. Analysis by Year of Partnership and Type of Partner
12.3.6. Analysis by Type of Partnership and Type of Partner
12.3.7. Most Active Players: Analysis by Number of Partnerships
12.3.8. Most Popular Technologies: Analysis by Number of Partnerships
12.3.9. Regional Analysis
12.3.9.1. Intercontinental and Intracontinental Agreements

13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. Antibody Discovery Service and Platform Providers: Funding and Investment Analysis
13.3.1. Analysis by Number of Funding Instances
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Most Active Players: Analysis by Amount Invested
13.3.5. Most Active Investors: Analysis by Number of Funding Instances
13.3.6. Regional Analysis by Amount Invested

13.4. Concluding Remarks

14. ANTIBODY DISCOVERY SERVICES: MARKET FORECAST
14.1. Chapter Overview
14.2. Forecast Methodology
14.3. Global Antibody Discovery Services Market, 2021-2035
14.4. Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2021-2035
14.4.1. Antibody Discovery Services Market for Antigen Designing, 2021-2035
14.4.2. Antibody Discovery Services Market for Hit Generation, 2021-2035
14.4.3. Antibody Discovery Services Market for Lead Selection, 2021-2035
14.4.4. Antibody Discovery Services Market for Lead Optimization, 2021-2035
14.4.5. Antibody Discovery Services Market for Lead Characterization, 2021-2035

14.5. Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2021-2035
14.5.1. Antibody Discovery Services Market for Phage Display, 2021-2035
14.5.2. Antibody Discovery Services Market for Yeast Display, 2021-2035
14.5.3. Antibody Discovery Services Market for Hybridoma Method, 2021-2035
14.5.4. Antibody Discovery Services Market for Transgenic Animal Based Method, 2021-2035
14.5.5. Antibody Discovery Services Market for Single Cell Based Method, 2021-2035
14.5.6. Antibody Discovery Services Market for Other Methods, 2021-2035

14.6. Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2021-2035
14.6.1. Antibody Discovery Services Market for Humanized Antibodies, 2021-2035
14.6.2. Antibody Discovery Services Market for Human Antibodies, 2021-2035
14.6.3. Antibody Discovery Services Market for Chimeric Antibodies, 2021-2035
14.6.4. Antibody Discovery Services Market for Murine Antibodies, 2021-2035

14.7. Global Antibody Discovery Services Market: Distribution by Region, 2021-2035
14.7.1. Antibody Discovery Services Market in North America, 2021-2035
14.7.2. Antibody Discovery Services Market in Europe, 2021-2035
14.7.3. Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2021-2035
14.7.4. Antibody Discovery Services: Market Attractiveness Analysis by Region

15. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET FORECAST
15.1. Chapter Overview
15.2. Key Assumptions
15.3. Forecast Methodology
15.4. Global Antibody Discovery Platforms Market, 2021-2035
15.5. Global Antibody Discovery Platforms Market: Distribution by Region, 2021-2035
15.5.1. Antibody Discovery Platforms Market in North America, 2021-2035
15.5.2. Antibody Discovery Platforms Market in Europe, 2021-2035
15.5.3. Antibody Discovery Platforms Market in Asia-Pacific, 2021-2035

16. LICENSING DEAL STRUCTURE

17. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
17.1. Chapter Overview
17.2. Humira® (Adalimumab)
17.2.1. Drug Overview
17.2.2. Discovery Process and Method
17.2.3. Historical Sales

17.3. Keytruda® (Pembrolizumab)
17.3.1. Drug Overview
17.3.2. Discovery Process and Method
17.3.3. Historical Sales

17.4. Stelara® (Ustekinumab)
17.4.1. Drug Overview
17.4.2. Discovery Process and Method
17.4.3. Historical Sales

17.5. Opdivo® (Nivolumab)
17.5.1. Drug Overview
17.5.2. Discovery Process and Method
17.5.3. Historical Sales

17.6. Avastin® (Bevacizumab)
17.6.1. Drug Overview
17.6.2. Discovery Process and Method
17.6.3. Historical Sales

18. CASE STUDY: ANTIBODY HUMANIZATION AND AFFINITY MATURATION
18.1. Importance of Antibody Humanization and Affinity Maturation
18.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: Market Landscape
18.3. Antibody Humanization: Publication Analysis
18.3.1. Publication Analysis: Year-Wise Trend
18.3.2. Publication Analysis: Key Journals
18.3.3. Publication Analysis: Distribution by Animal Model Used
18.3.4. Publication Analysis: Distribution by Antibody Humanization Method
18.4. Antibody Humanization Service and Platform Providers: SWOT Analysis

19. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
19.1. Chapter Overview
19.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Antibody Formats
19.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
19.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
19.5. Rising Demand for Antibody-based Treatment Options for Non-Oncological Indications
19.6. Future Growth Opportunities in the Asia-Pacific Region
19.7. Expected Increase in Number of Collaborations and Licensing Activity
19.8 Concluding Remarks

20. CONCLUDING REMARKS
20.1. Chapter Overview

21. EXECUTIVE INSIGHTS
21.1. Chapter Overview

21.2. Abveris Antibody
21.2.1. Company Snapshot
21.2.2. Tracey Mullen, Chief Executive Officer (Q2 2020)

21.3. Nidus Biosciences
21.3.1. Company Snapshot
21.3.2. Lisa Delouise, Founder and Chief Technology Officer (Q1 2020)

21.4. AvantGen
21.4.1. Company Snapshot
21.4.2. Mark Kubik, Chief Business Officer(Q1 2020)

21.5. Single Cell Technology
21.5.1. Company Snapshot
21.5.2. Chun-Nan Chen, Chief Executive Officer and Chief Scientific Officer (Q2 2018)

21.6. Distributed Bio
21.6.1. Company Snapshot
21.6.2. Giles Day, Co-Founder and Chief Executive Officer (Q2 2018)

21.7. AbCellera
21.7.1. Company Snapshot
21.7.2. Kevin Heyries, Co-Founder and Lead of Business Development Strategy (Q2 2018)

21.8. AbGenics Life Sciences
21.8.1. Company Snapshot
21.8.2. Sanjiban K Banerjee, Director (Q2 2018)

21.9. CDI Laboratories
21.9.1. Company Snapshot
21.9.2. Ignacio Pino, Chief Executive Officer and President (Q2 2017)

21.10. AP Biosciences
21.10.1. Company Snapshot
19.10.2. Jeng Her, Chief Executive Officer (Q2 2017)

21.11. YUMAB
21.11.1. Company Snapshot
21.11.2. Thomas Schirrmann, Chief Executive Officer and General Manager (Q2 2017)

21.12. Antibody Solutions
21.12.1. Company Snapshot
21.12.2. Debra Valsamis, Business Development Associate (Q2 2017)

21.13. Ligand Pharmaceuticals
21.13.1. Company Snapshot
21.13.2. Christel Iffland, Vice President (Q2 2017)

21.14. LakePharma
21.14.1. Company Snapshot
21.14.2. Aaron Sato, Chief Scientific Officer (Q2 2017)

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 3.1 Basic Structure of an Antibody
Figure 3.2 Historical Timeline of Antibody Development
Figure 3.3 Mechanism of Action of Antibodies
Figure 3.4 Applications of Antibodies
Figure 4.1 Overview of the Antibody Discovery Process
Figure 4.2 Antibody Discovery Process: Hybridoma Method
Figure 4.3 Antibody Discovery Process: Phage Display Method
Figure 4.4 Antibody Generation Using Transgenic Animals
Figure 4.5 Approved Monoclonal Antibodies: Development Trend Analysis
Figure 4.6 Approval Timeline of Fully Human Monoclonal Antibodies
Figure 4.7 Discovery Methods of Fully Human Monoclonal Antibodies
Figure 5.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
Figure 5.2 Antibody Discovery Service Providers: Distribution by Company Size
Figure 5.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters
Figure 5.4 World Map Representation: Distribution by Location by Headquarters
Figure 5.5 Antibody Discovery Service Providers: Distribution by Type of Service Offered
Figure 5.6 Antibody Discovery Service Providers: Distribution by Company Size and Type of Service Offered
Figure 5.7 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Figure 5.8 Grid Representation: Distribution by Type of Antibody Discovery Method, Type of Antibody Discovered and Location of Headquarters
Figure 5.9 Antibody Discovery Service Providers: Distribution by Animal Model Used
Figure 5.10 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Figure 5.11 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method and Type of Antibody Discovered
Figure 5.12 Antibody Discovery Service Providers: Distribution by Purpose of Antibody Discovery
Figure 6.1 Competitiveness Analysis: Antibody Discovery Service Providers based in North America
Figure 6.2 Competitiveness Analysis: Antibody Discovery Service Providers based in Europe
Figure 6.3 Competitiveness Analysis: Antibody Discovery Service Providers based in Asia-Pacific
Figure 7.1 Abzena: Annual Revenues, 2014-2018 (GBP Million)
Figure 7.2 ImmunoPrecise Antibodies: Annual Revenues, 2016-2021 (USD Million)
Figure 7.3 Viva Biotech: Annual Revenues, 2016-H1 2021 (RMB Million)
Figure 7.4 WuXi Biologics: Annual Revenues, 2015-H1 2021 (RMB Billion)
Figure 8.1 Antibody Discovery Platform Providers: Distribution by Year of Establishment
Figure 8.2 Antibody Discovery Platform Providers: Distribution by Company Size
Figure 8.3 Antibody Discovery Platform Providers: Distribution by Location of Headquarters
Figure 8.4 World Map Representation: Distribution by Location by Headquarters
Figure 8.5 Antibody Discovery Platform Providers: Distribution by Type of Antibody Discovered
Figure 8.6 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method
Figure 8.7 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method and Location of Headquarters
Figure 8.8 Antibody Discovery Platforms: Distribution by Animal Model Used
Figure 8.9 Antibody Discovery Platforms: Distribution by Patent Availability
Figure 9.1 Competitiveness Analysis: Library based Antibody Discovery Platforms
Figure 9.2 Competitiveness Analysis: Single Cell based Antibody Discovery Platforms
Figure 9.3 Competitiveness Analysis: Transgenic Animal based Antibody Discovery Platforms
Figure 9.4 Competitiveness Analysis: Hybridoma based Antibody Discovery Platforms
Figure 9.5 Competitiveness Analysis: Other Antibody Discovery Platforms
Figure 10.1 ImmunoPrecise Antibodies: Annual Revenues, 2016-2021 (USD Million)
Figure 10.2 Ligand Pharmaceuticals: Annual Revenues, 2014-9M 2021 (USD Million)
Figure 10.3 MorphoSys: Annual Revenues, 2014-9M 2021 (USD Million)
Figure 11.1 Regional Capability Analysis: Antibody Discovery Service Providers based in North America
Figure 11.2 Regional Capability Analysis: One-Stop Shops in North America
Figure 11.3 Regional Capability Analysis: Antibody Discovery Service Providers based in Europe
Figure 11.4 Regional Capability Analysis: One-Stop Shops in Europe
Figure 11.5 Regional Capability Analysis: Antibody Discovery Service Providers based in Asia-Pacific
Figure 11.6 Regional Capability Analysis: One-Stop Shops in Asia-Pacfic
Figure 11.7 Regional Capability Analysis: Concluding Remarks
Figure 12.1 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2021
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2020
Figure 12.4 Partnerships and Collaborations: Distribution by Type of Company (Service / Platform Providers)
Figure 12.5 Partnerships and Collaborations: Distribution by Type of Antibody Discovered
Figure 12.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 12.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 12.8 Most Active Players: Distribution by Number of Partnerships
Figure 12.9 Most Popular Technologies: Distribution by Number of Partnerships
Figure 12.10 Partnerships and Collaborations: Regional Distribution
Figure 12.11 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 13.1 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment
Figure 13.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2016-2021
Figure 13.3 Funding and Investment Analysis: Year-wise Distribution of Funding Instances by Type of Company, (2016-2021)
Figure 13.4 Funding and Investment Analysis: Distribution by Cumulative Amount Invested, 2016-2021 (USD Million)
Figure 13.5 Funding and Investment Analysis: Year-wise Distribution of Funding Instances by Amount Invested, 2016-2021 (USD Million)
Figure 13.6 Funding and Investment Analysis: Year-wise Distribution of the Amount Raised by Type of Company, 2016-2021 (USD Million)
Figure 13.7 Funding and Investment Analysis: Distribution of Instances by Type of Funding,
Figure 13.8 Funding and Investment Analysis: Distribution of Type of Funding and Amount Invested, (USD Million)
Figure 13.9 Most Active Player: Distribution by Number of Funding Instances
Figure 13.10 Most Active Player: Distribution by Total Amount Invested (USD Million)
Figure 13.11 Most Active Investors: Distribution by Number of Funding Instances
Figure 13.12 Funding and Investment Analysis: Distribution by Geography
Figure 13.13 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 13.14 Funding and Investment Summary
Figure 14.1 Global Antibody Discovery Services Market, 2021-2035 (USD Billion)
Figure 14.2 Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2021-2035 (USD Billion)
Figure 14.3 Antibody Discovery Services Market for Antigen Designing, 2021-2035 (USD Billion)
Figure 14.4 Antibody Discovery Services Market for Hit Generation, 2021-2035 (USD Billion)
Figure 14.5 Antibody Discovery Services Market for Lead Selection, 2021-2035 (USD Billion)
Figure 14.6 Antibody Discovery Services Market for Lead Optimization, 2021-2035 (USD Billion)
Figure 14.7 Antibody Discovery Services Market for Lead Characterization, 2021-2035 (USD Billion)
Figure 14.8 Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2021-2035 (USD Billion)
Figure 14.9 Antibody Discovery Services Market for Phage Display, 2021-2035 (USD Billion)
Figure 14.10 Antibody Discovery Services Market for Yeast Display, 2021-2035 (USD Billion)
Figure 14.11 Antibody Discovery Services Market for Hybridoma Method, 2021-2035 (USD Billion)
Figure 14.12 Antibody Discovery Services Market for Transgenic Animal based Method, 2021-2035 (USD Billion)
Figure 14.13 Antibody Discovery Services Market for Single Cell based Method, 2021-2035 (USD Billion)
Figure 14.14 Antibody Discovery Services Market for Other Methods, 2021-2035 (USD Billion)
Figure 14.15 Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2021-2035 (USD Billion)
Figure 14.16 Antibody Discovery Services Market for Humanized Antibodies, 2021-2035 (USD Billion)
Figure 14.17 Antibody Discovery Services Market for Human Antibodies, 2021-2035 (USD Billion)
Figure 14.18 Antibody Discovery Services Market for Chimeric Antibodies, 2021-2035 (USD Billion)
Figure 14.19 Antibody Discovery Services Market for Murine Antibodies, 2021-2035 (USD Billion)
Figure 14.20 Global Antibody Discovery Services Market: Distribution by Region, 2021-2035 (USD Billion)
Figure 14.21 Antibody Discovery Services Market in North America, 2021-2035 (USD Billion)
Figure 14.22 Antibody Discovery Services Market in Europe, 2021-2035 (USD Billion)
Figure 14.23 Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2021-2035 (USD Billion)
Figure 14.24 Antibody Discovery Services: Market Attractiveness Analysis by Region (USD Billion)
Figure 15.1 Licensing Agreements: Distribution of Financial Components
Figure 15.2 Technology Licensing Deal: Payment Structure
Figure 15.3 Global Antibody Discovery Platforms Market, 2021-2035 (USD Million)
Figure 15.4 Global Antibody Discovery Platforms Market: Distribution by Region, 2021-2035 (USD Million)
Figure 15.5 Antibody Discovery Platforms Market in North America, 2021-2035 (USD Million)
Figure 15.6 Antibody Discovery Platforms Market in Europe, 2021-2035 (USD Million)
Figure 15.7 Antibody Discovery Platforms Market in Asia-Pacific, 2021-2035 (USD Million)
Figure 16.1 Humira®: Annual Sales, 2016-9M 2021 (USD Billion)
Figure 16.2 Keytruda®: Annual Sales, 2016-9M 2021 (USD Billion)
Figure 16.3 Stelara®: Annual Sales, 2016-9M 2021 (USD Billion)
Figure 16.4 Opdivo®: Annual Sales, 2016-9M 2021 (USD Billion)
Figure 16.5 Avastin®: Annual Sales, 2016-9M 2021 (CHF Million)
Figure 17.1 Publication Analysis: Year-wise Distribution of Publications, 2014-2017
Figure 17.2 Publication Analysis: Distribution by Key Journals
Figure 17.3 Publication Analysis: Distribution by Animal Model Used
Figure 17.4 Publication Analysis: Distribution by Antibody Humanization Method Used
Figure 17.6 Antibody Humanization Service and Platform Providers: SWOT Analysis
Figure 17.7 Antibody Humanization Service and Platform Providers: Strengths Overview
Figure 17.8 Antibody Humanization Service and Platform Providers: Weaknesses Overview
Figure 17.9 Antibody Humanization Service and Platform Providers: Opportunities Overview
Figure 17.10 Antibody Humanization Service and Platform Providers: Threats Overview
Figure 18.1 Future Opportunities Related to Upcoming Trends in Drug Discovery
Figure 18.2 Number of Licensing Deals, 2015- 2021

List Of Tables

Table 3.1 Antibody Isotypes: Key Features
Table 3.2 Mechanism of Action of Therapeutic Antibodies against Different Target Classes
Table 3.3 Differences Between Polyclonal and Monoclonal Antibodies
Table 4.1 Antibody Discovery Methods: Advantages and Disadvantages
Table 4.2 List of Approved Monoclonal Antibodies
Table 5.1 List of Antibody Discovery Service Providers
Table 5.2 Antibody Discovery Service Providers: Information on Type of Service(s) Offered
Table 5.3 Antibody Discovery Service Providers: Information on Type of Antibody Discovery Method(s)
Table 5.4 Antibody Discovery Service Providers: Information on Animal Model Used
Table 5.5 Antibody Discovery Service Providers: Information on Type of Antibody Discovered
Table 5.6 Antibody Discovery Service Providers: Information on Purpose of Antibody Discovery
Table 7.1 Antibody Discovery Service Providers: List of Companies Profiled
Table 7.2 Abwiz Bio: Recent Developments and Future Outlook
Table 7.3 Aragen Bioscience: Recent Developments and Future Outlook
Table 7.4 Creative Biolabs: Recent Developments and Future Outlook
Table 7.4 Distributed Bio: Recent Developments and Future Outlook
Table 7.5 ImmunoPrecise Antibodies: Recent Developments and Future Outlook
Table 7.6 Integral Molecular: Recent Developments and Future Outlook
Table 7.7 LakePharma: Recent Developments and Future Outlook
Table 7.8 Abzena: Recent Developments and Future Outlook
Table 7.9 BIOTEM: Recent Developments and Future Outlook
Table 7.10 PX'Therapeutics: Recent Developments and Future Outlook
Table 7.11 ChemPartner: Recent Developments and Future Outlook
Table 7.12 Viva Biotech: Recent Developments and Future Outlook
Table 7.13 WuXi Biologics: Recent Developments and Future Outlook
Table 8.1 List of Antibody Discovery Platform Providers
Table 8.2 Antibody Discovery Platform Providers: Information on Type of Antibody Discovered
Table 8.3 Antibody Discovery: List of Technologies and Platforms
Table 8.4 Antibody Discovery Platforms: Information on Type of Antibody Discovery Method(s)
Table 8.5 Antibody Discovery Platforms: Information on Animal Model Used
Table 8.6 Antibody Discovery Platforms: Information on Patent Availability
Table 10.1 Antibody Discovery Platform Providers: List of Companies Profiled
Table 10.2 Harbour BioMed: Recent Developments and Future Outlook
Table 10.3 ImmunoPrecise Antibodies: Recent Developments and Future Outlook
Table 10.4 Kymab: Recent Developments and Future Outlook
Table 10.5 OmniAb® Technology: Patent Information
Table 10.6 OmniChicken® Technology: Patent Information
Table 10.7 Ligand Pharmaceuticals: Recent Developments and Future Outlook
Table 10.8 MorphoSys: Recent Developments and Future Outlook
Table 11.1 Regional Capability Analysis: Antibody Discovery Platform Providers based in North America
Table 11.2 Regional Capability Analysis: Antibody Discovery Platform Providers based in Europe
Table 11.3 Regional Capability Analysis: Antibody Discovery Platform Providers based in Asia-Pacific
Table 12.1 Antibody Discovery Service and Platform Providers: List of Partnerships and Collaboration, 2015-2021
Table 13.1 Antibody Discovery Service and Platform Providers: List of Funding Instances, 2016-2021
Table 13.2 Funding and Investment Analysis: Summary of Investments
Table 15.1 Developmental / Regulatory Milestones
Table 15.2 Antibody Discovery Platforms: Average Upfront and Average Milestone Payments (USD Million)
Table 16.1 List of Top Ten Selling Therapeutic Antibodies, 2020
Table 17.1 Approved Monoclonal Antibodies: Information on Affinity
Table 17.2 Antibody Humanization and Affinity Maturation: Service and Platform Providers
Table 17.3 Antibody Humanization and Affinity Maturation: Methods Employed by Service and Platform Providers
Table 17.4 Antibody Humanization: List of Recent Publications
Table 17.5 Antibody Humanization: Modified CDR Grafting Methods
Table 18.1 Antibody Discovery Services and Platform Providers: Asia-Pacific Region
Table 19.1 Abveris Antibody: Company Snapshot
Table 19.2 Nidus Biosciences: Company Snapshot
Table 19.3 AvantGen: Company Snapshot
Table 19.4 Single Cell Technology: Company Snapshot
Table 19.5 Distributed Bio: Company Snapshot
Table 19.6 AbCellera: Company Snapshot
Table 19.7 AbGenics Life Sciences: Company Snapshot
Table 19.8 CDI Laboratories: Company Snapshot
Table 19.9 AP Biosciences: Company Snapshot
Table 19.10 YUMAB: Company Snapshot
Table 19.12 Antibody Solutions: Company Snapshot
Table 19.13 Ligand Pharmaceuticals: Company Snapshot
Table 19.14 LakePharma: Company Snapshot
Table 21.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
Table 21.2 Antibody Discovery Service Providers: Distribution by Company Size
Table 21.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters
Table 21.4 Antibody Discovery Service Providers: Distribution by Type of Service Offered
Table 21.5 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Table 21.6 Antibody Discovery Service Providers: Distribution by Animal Model Used
Table 21.7 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Table 21.8 Antibody Discovery Service Providers: Distribution by Purpose of Antibody Discovery
Table 21.9 Abzena: Annual Revenues, 2014-2018 (GBP Million)
Table 21.10 ImmunoPrecise Antibodies: Annual Revenues, 2016-2021 (USD Million)
Table 21.11 Viva Biotech: Annual Revenues, 2016-H1 2021 (RMB Million)
Table 21.12 WuXi Biologics: Annual Revenues, 2015-H1 2021 (RMB Billion)
Table 21.13 Antibody Discovery Platform Providers: Distribution by Year of Establishment
Table 21.14 Antibody Discovery Platform Providers: Distribution by Company Size
Table 21.15 Antibody Discovery Platform Providers: Distribution by Location of Headquarters
Table 21.16 Antibody Discovery Platform Providers: Distribution by Type of Antibody Discovered
Table 21.17 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method
Table 21.18 Antibody Discovery Platforms: Distribution by Animal Model Used
Table 21.19 Antibody Discovery Platforms: Distribution by Patent Availability
Table 21.20 ImmunoPrecise Antibodies: Annual Revenues, 2016-2021 (USD Million)
Table 21.21 Ligand Pharmaceuticals: Annual Revenues, 2014-9M 2021 (USD Million)
Table 21.22 MorphoSys: Annual Revenues, 2014-9M 2021 (USD Million)
Table 21.23 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2021
Table 21.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 21.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2020
Table 21.26 Partnerships and Collaborations: Distribution by Type of Company (Service / Platform Providers)
Table 21.27 Partnerships and Collaborations: Distribution by Type of Antibody Discovered
Table 21.28 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 21.29 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 21.30 Most Active Players: Distribution by Number of Partnerships
Table 21.31 Most Popular Technologies: Distribution by Number of Partnerships
Table 21.32 Partnerships and Collaborations: Regional Distribution
Table 21.33 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment
Table 21.34 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2016-2021
Table 21.35 Funding and Investment Analysis: Year-wise Distribution of Funding Instances by Type of Company, (2016-2021)
Table 21.36 Funding and Investment Analysis: Distribution by Cumulative Amount Invested, 2016-2021 (USD Million)
Table 21.37 Funding and Investment Analysis: Year-wise Distribution of Funding Instances by Amount Invested, 2016-2021 (USD Million)
Table 21.38 Funding and Investment Analysis: Year-wise Distribution of the Amount Raised by Type of Company, 2016-2021 (USD Million)
Table 21.39 Funding and Investment Analysis: Distribution of Instances by Type of Funding,
Table 21.40 Funding and Investment Analysis: Distribution of Type of Funding and Amount Invested, (USD Million)
Table 21.41 Most Active Player: Distribution by Number of Funding Instances
Table 21.42 Most Active Player: Distribution by Total Amount Invested (USD Million)
Table 21.43 Most Active Investors: Distribution by Number of Funding Instances
Table 21.44 Funding and Investment Analysis: Distribution by Geography
Table 21.45 Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 21.46 Global Antibody Discovery Services Market, 2021-2035 (USD Billion): Base, Conservative and Optimistic Scenarios
Table 21.47 Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2021-2035: Base, Conservative and Optimistic Scenarios
Table 21.48 Antibody Discovery Services Market for Antigen Designing, 2021-2035
Table 21.49 Antibody Discovery Services Market for Hit Generation, 2021-2035
Table 21.50 Antibody Discovery Services Market for Lead Selection, 2021-2035
Table 21.51 Antibody Discovery Services Market for Lead Optimization, 2021-2035
Table 21.52 Antibody Discovery Services Market for Lead Characterization, 2021-2035
Table 21.53 Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2021-2035: Base, Conservative and Optimistic Scenarios
Table 21.54 Antibody Discovery Services Market for Phage Display, 2021-2035
Table 21.55 Antibody Discovery Services Market for Yeast Display, 2021-2035
Table 21.56 Antibody Discovery Services Market for Hybridoma Method, 2021-2035
Table 21.57 Antibody Discovery Services Market for Transgenic Animal Based Method, 2021-2035
Table 21.58 Antibody Discovery Services Market for Single Cell Based Method, 2021-2035
Table 21.59 Antibody Discovery Services Market for Other Methods, 2021-2035
Table 21.60 Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2021-2035: Base, Conservative and Optimistic Scenarios
Table 21.61 Antibody Discovery Services Market for Humanized Antibodies, 2021-2035
Table 21.62 Antibody Discovery Services Market for Human Antibodies, 2021-2035
Table 21.63 Antibody Discovery Services Market for Chimeric Antibodies, 2021-2035
Table 21.64 Antibody Discovery Services Market for Murine Antibodies, 2021-2035

Table 21.65 Global Antibody Discovery Services Market: Distribution by Region, 2021-2035: Base, Conservative and Optimistic Scenarios
Table 21.66 Antibody Discovery Services Market in North America, 2021-2035
Table 21.67 Antibody Discovery Services Market in Europe, 2021-2035
Table 21.68 Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2021-2035
Table 21.69 Global Antibody Discovery Platforms Market, 2021-2035 (USD Million): Base, Conservative and Optimistic Scenarios
Table 21.70 Global Antibody Discovery Platforms Market: Distribution by Region, 2021-2035 (USD Million): Base, Conservative and Optimistic Scenarios
Table 21.71 Antibody Discovery Platforms Market in North America, 2021-2035
Table 21.72 Antibody Discovery Platforms Market in Europe, 2021-2035
Table 21.73 Antibody Discovery Platforms Market in Asia-Pacific, 2021-2035
Table 21.74 Humira®: Annual Sales, 2016-9M 2021 (USD Billion)
Table 21.75 Keytruda®: Annual Sales, 2016-9M 2021 (USD Billion)
Table 21.76 Stelara®: Annual Sales, 2016-9M 2021 (USD Billion)
Table 21.77 Opdivo®: Annual Sales, 2016-9M 2021 (USD Billion)
Table 21.78 Avastin®: Annual Sales, 2016-9M 2021 (CHF Million)
Table 21.79 Number of Licensing Deals, 2015- 2021

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 2BScientific
  2. 3D Medicines 
  3. 3E Bioventures Capital
  4. 3SBio
  5. A*STAR's Genome Institute of Singapore
  6. AAT Bioquest 
  7. Ab Initio Biotherapeutics
  8. Ab Studio
  9. ABBA Therapeutics
  10. AbBioSci
  11. Abbiotec
  12. AbbVie
  13. Abcam
  14. AbCellera
  15. Abcentra
  16. Abcepta
  17. AbCheck
  18. ABclonal 
  19. Abcore 
  20. ABDYS
  21. Abeome
  22. Abexxa Biologics 
  23. ABGENEX
  24. AbGenics Life Sciences
  25. Abilita Bio
  26. ABL Bio
  27. Ablexis
  28. Abnova
  29. Abpro
  30. AbSano
  31. Absea  
  32. Absolute Antibody
  33. Abveris 
  34. AbVision
  35. Abwiz Bio
  36. Abzena
  37. Abzyme Therapeutics
  38. AC Immune
  39. Accel
  40. Acceleron Pharma
  41. Accurus Biosciences
  42. Achaogen
  43. ACYTE Biotech
  44. Adagene
  45. Adaptate Biotherapeutics
  46. Adimab
  47. Adipogen Life Sciences 
  48. Aduro Biotech
  49. Advantech
  50. Advantech Capital
  51. AffinityImmuno
  52. Affitech
  53. Agency for Science, Technology and Research
  54. Agenus
  55. Agro-Bio 
  56. AIMM Therapeutics
  57. Aimmune Therapeutics
  58. Aisling Capital
  59. Akeagen 
  60. Akeso Biopharma
  61. Aldevron
  62. Alector
  63. Alligator Bioscience
  64. Allogene Therapeutics
  65. Alloy Therapeutics
  66. Ally Bridge 
  67. AlpaLife 
  68. Alta Partners
  69. Alvaxa Biosciences (Acquired by Sensei Biotherapeutics)
  70. ALX Oncology 
  71. alytas therapeutics 
  72. Alzheimer's Drug Discovery Foundation
  73. Amgen
  74. Amgen Ventures
  75. Ampersand Capital Partners
  76. AMSBIO
  77. AnaImmune
  78. Analytics Engine
  79. AnaptysBio
  80. Andera Partners
  81. Angel BioScience
  82. Antagene
  83. Antibody Design Labs
  84. Antibody Solutions
  85. Antiverse
  86. AP Biosciences
  87. Apexigen
  88. APITBIO 
  89. Applied Biological Materials(abm)
  90. AprilBio
  91. Aptevo Therapeutics
  92. Aquila BioMedical
  93. Aquila Capital
  94. Aquilo Capital Management
  95. Aragen Bioscience
  96. ARCH Venture Partners
  97. Arcus Biosciences
  98. argenx
  99. Aridis Pharmaceuticals
  100. Aro Biotherapeutics
  101. Aronora
  102. Arsanis
  103. ArtiaBio 
  104. Artizan Biosciences
  105. ARVYS Proteins 
  106. Assistant Secretary for Preparedness and Response
  107. Astellas Pharma
  108. AstraZeneca
  109. aTen Therapeutics
  110. Atreca
  111. ATUM
  112. Autolus Therapeutics
  113. AvantGen
  114. AVIC Capital
  115. Aviva Systems Biology 
  116. AxioMx
  117. Ballast Point Ventures
  118. Bayer
  119. BBI Group
  120. BeiGene
  121. Beijing Shijilongxin Investment
  122. BenchSci 
  123. Berkeley Lights
  124. Betta Pharmaceuticals
  125. BRL
  126. Bharat Innovation Fund
  127. Bhat Bio-tech
  128. Bill & Melinda Gates Foundation
  129. Bio- Rad Laboratories
  130. BioAtla
  131. BioConnect
  132. Biocure Technology 
  133. Biocytogen
  134. BioDiscovery
  135. BioDuro
  136. Biogen
  137. Biointron
  138. BioInvent
  139. BiologicsCorp(BIC)
  140. Biomatics Capital
  141. Biomolecular Discovery Services
  142. BioNTech
  143. Bio-Rad Laboratories
  144. BioSavita
  145. Biosion
  146. Biotechnology Value Fund
  147. Biotecnol
  148. BIOTEM
  149. Biotheus
  150. Bioz 
  151. Birchmere Labs
  152. Bird Rock Bio
  153. Blue Sky BioServices
  154. bluebird bio
  155. Boehringer Ingelheim
  156. Boster Bio
  157. Boston Children's Hospital
  158. Boxer Capital
  159. Brain Canada
  160. Bristol-Myers Squibb
  161. Broteio Pharma
  162. Burrage Capital
  163. CALIXAR
  164. CANbridge
  165. Cancer Prevention and Research Institute of Texas
  166. Capra Science 
  167. Capralogics 
  168. Carterra
  169. Catalent Biologics
  170. CBC Group
  171. CCB Capital
  172. CDH Investments
  173. CDI Laboratories
  174. Celexion
  175. Celgene
  176. Cell Signaling Technology
  177. Cellaria
  178. Celsius Therapeutics
  179. Centers for Disease Control and Prevention (CDC)
  180. Charles River Laboratories
  181. ChemBio Discovery Solutions
  182. Chemical Abstracts Service (CAS)
  183. ChemPartner
  184. Chia Tai Tianqing Pharmaceutical 
  185. China Life Investment Holding
  186. China Life Private Equity Investment
  187. ChinaEquity Group (CEG)
  188. Chiome Bioscience
  189. Chugai Pharmabody Research
  190. Chugai Pharmaceutical
  191. Cilag
  192. Citryll
  193. City of Hope
  194. Columbia University Irving Medical Center
  195. Compass Therapeutics
  196. Cormorant Asset Management
  197. Corvidia Therapeutics
  198. Cosmo Bio
  199. Cowen Healthcare Investments
  200. Cowin Venture Capital
  201. CR-CP Life Science Fund
  202. Creative Biolabs
  203. Creative Biostructure
  204. Creative Diagnostics
  205. Crescendo Biologics
  206. Crystal Bioscience
  207. CSL Behring
  208. CStone Pharmaceuticals
  209. CureVac
  210. CUSABIO
  211. Cyclogenix 
  212. Cygnus Technologies 
  213. DAFNA Capital Management
  214. Daiichi Sankyo
  215. Dako
  216. Dana-Farber Cancer Institute
  217. DaTaMabs
  218. DBA ITALIA
  219. DCVC (Data Collective) 
  220. Decheng Capital
  221. Defense Advanced Research Projects Agency (DARPA)
  222. Delian Capital
  223. Denali Therapeutics
  224. Detaibio Tech 
  225. Diagnostic BioSystems 
  226. Dianomi Therapeutics
  227. Diatheva
  228. Digital Proteomics
  229. Distributed Bio
  230. DJS Antibodies
  231. Dotmatics
  232. Dualogics 
  233. Early Drug Development Group (E2DG)
  234. EcoR1 Capital
  235. Efung Capital
  236. Eight Roads
  237. Eisai
  238. Elabscience 
  239. Eli Lilly and Company
  240. Elpis Biopharmaceuticals
  241. Emergent BioSolutions
  242. E-nnovation Life Sciences
  243. Enterprise Singapore
  244. Enthera
  245. Entos Pharmaceuticals
  246. Envigo
  247. EpimAb Biotherapeutics
  248. Epiphron Capital Group
  249. EUPROTEIN
  250. Eureka Therapeutics
  251. European Investment Bank
  252. European Molecular Biology Laboratory (EMBL)
  253. Eurostars
  254. Evotec
  255. Exelixis
  256. Exiris
  257. exonbio
  258. FairJourney Biologics
  259. Faron Pharmaceuticals
  260. FCMI Parent
  261. Ferring Pharmaceuticals
  262. Five Prime Therapeutics
  263. Flagship Pioneering
  264. Flanders Innovation and Entrepreneurship
  265. Floodgate
  266. ForteBio
  267. Fortune Capital Services
  268. Forty Seven
  269. F-Prime Capital
  270. Fred Hutchinson Cancer Research Center
  271. FREJOY Investment Management
  272. Fusion Antibodies
  273. Fusion Pharmaceuticals
  274. G&P Biosciences
  275. G.N. Tech Venture
  276. Genagon Therapeutics
  277. Gene Techno Science
  278. GeneBeyond
  279. Genedata Biologics
  280. GeneFrontier
  281. Geneious Biologics
  282. General Atlantic
  283. GENEWIZ 
  284. Genmab
  285. Genor Biopharma
  286. GenoSafe 
  287. Genosco
  288. GenScript
  289. GenWay Biotech 
  290. GHO Capital
  291. GIC
  292. GigaGen
  293. Gilead Sciences
  294. GSK
  295. Glenmark Pharmaceuticals
  296. Glythera
  297. Gopher Asset Management
  298. GP Healthcare Capital
  299. Green Mountain Antibodies 
  300. Grenoble Alpes University Hospital
  301. Grifols
  302. Gustave Roussy
  303. GV20 Oncotherapy
  304. H3 Biomedicine
  305. Harbour BioMed
  306. Harpoon Therapeutics
  307. HD Biosciences
  308. Helix BioPharma
  309. Henlix Biotech
  310. Heptares Therapeutics
  311. Hercules Capital
  312. Heritas Capital Management
  313. HiFiBiO Therapeutics
  314. Hillhouse Capital 
  315. HJB
  316. Hony Capital
  317. HOPU Investments
  318. Horizon Discovery 
  319. Huaxing Growth Capital
  320. Hummingbird Bioscience
  321. i2 Pharmaceuticals
  322. Ibex Biosciences
  323. Icosagen
  324. IDG Capital
  325. IFB Hamburg
  326. IGEM Therapeutics
  327. I-Mab Biopharma
  328. iMetabolic Biopharma
  329. Immatics Biotechnologies
  330. Immune Biosolutions
  331. Immune Pharmaceuticals
  332. ImmunoChina Pharmaceuticals
  333. ImmunoGenes
  334. Immunome
  335. Immunomic Therapeutics
  336. ImmunoPrecise Antibodies
  337. ImmunoQure
  338. In-Cell-Art
  339. Incyte
  340. Indivumed
  341. Inhibrx
  342. Innate Pharma
  343. Innogene Kalbiotech
  344. Innovagen  
  345. Innovate UK
  346. Innovative Targeting Solutions
  347. Innovent Biologics
  348. Inotiv 
  349. Institut National de la Santé et de la Recherche Médicale (INSERM)
  350. Institute for Research in Biomedicine
  351. Intarcia Therapeutics
  352. Integral Molecular
  353. IntelliCyt
  354. International Livestock Research Institute (ILRI) 
  355. Invenra
  356. Invest Northern Ireland
  357. Invetx 
  358. IONTAS
  359. IP  
  360. IRBM
  361. Isogenica
  362. Italian National Institute of Health
  363. ITBMed
  364. iTeos Therapeutics
  365. Janssen Biotech
  366. Janssen Pharmaceutical
  367. JDRF T1D Fund
  368. Jiangsu Hengrui Medicine
  369. Johnson & Johnson Innovation
  370. Jounce Therapeutics
  371. Juno Therapeutics
  372. Just Biotherapeutics (Acquired by Evotec)
  373. JW Bioscience
  374. Kadmon
  375. Kairos Therapeutics 
  376. Kaken Pharmaceutical
  377. Karolinska Institutet
  378. Kemp Proteins (formerly known as Kempbio)
  379. Keystone Capital Partners
  380. Kite Pharma
  381. KMD 
  382. Kodiak Sciences
  383. Kymab
  384. LabCorp
  385. Labtoo
  386. LakePharma
  387. LAMPIRE Biological Laboratories
  388. Lanier Biotherapeutics
  389. Lava Therapeutics
  390. Leadgene Biomedical
  391. Leading Biology
  392. Legend Capital
  393. Legend Star
  394. Leidos Biomedical Research
  395. LEO Pharma
  396. LG Chem
  397. Life Science Partners
  398. LifeArc
  399. LifeTein
  400. Ligand Pharmaceuticals
  401. Light Chain Bioscience
  402. Lilly Ventures
  403. Lineage Biosciences (Acquired by AbCellera)
  404. Linear Venture
  405. Lipum
  406. Lonza
  407. Lundbeck
  408. Luye Pharma  
  409. LYFE Capital
  410. MAB Discovery
  411. MabGenesis
  412. Mablytics
  413. Mabpharm
  414. MAbSilico 
  415. MabSpace Biosciences
  416. Mabtech
  417. MabVax Therapeutics
  418. MacroGenics
  419. Magenta Therapeutics
  420. Maine Biotechnology Services
  421. Malin
  422. Maravai LifeSciences 
  423. Massachusetts General Hospital
  424. MassBiologics
  425. Maverick Therapeutics
  426. MD Anderson Cancer Center
  427. MedAbome
  428. Medicilon
  429. MedImmune
  430. Medix Biochemica 
  431. MEMO Therapeutics
  432. Memorial Sloan Kettering Cancer Center
  433. Merck
  434. Merus
  435. MI-mAbs 
  436. Mirae Asset Financial 
  437. Mitsubishi Tanabe Pharma
  438. Mitsubishi UFJ Capital
  439. ModiQuest Research
  440. Molcure
  441. Molecular Devices
  442. Molecular Templates
  443. MolMed
  444. Moradec
  445. MorphoSys
  446. Mount Sinai Health System
  447. MPM Capital
  448. MRL Ventures Fund
  449. MSM Protein Technologies
  450. Mycenax Biotech
  451. Myrio Therapeutics (Myrio)
  452. NanoString Technologies
  453. Nara Medical University 
  454. National Cancer Institute
  455. National Center for Research and Development
  456. National Centre for Biomolecular Research
  457. National Heart, Lung and Blood Institute
  458. National Institute of Allergy and Infectious Diseases
  459. National Institute of General Medical Sciences
  460. National Institutes of Health
  461. NB Health Laboratory
  462. NBE-Therapeutics
  463. NeoBiotechnologies
  464. NeoClone
  465. Neon Therapeutics
  466. neoX Biotech
  467. Nest.Bio Ventures
  468. Neurimmune
  469. New World TMT
  470. Nidus BioSciences
  471. NJCTTQ
  472. Nkarta Therapeutics
  473. North Coast Biologics
  474. NovaRock Biotherapeutics
  475. Novartis
  476. Novo Nordisk
  477. Numab Therapeutics
  478. NYU Langone Health
  479. Oak Biosciences 
  480. Oblique Therapeutics
  481. Oceanpine Capital
  482. Olympic Protein Technologies
  483. Oncothyreon
  484. Ono Pharmaceutical
  485. Open Monoclonal Technology
  486. OrbiMed Advisors
  487. OREGA Biotech
  488. ORI Healthcare Fund
  489. OriGene Technologies
  490. OriMAbs
  491. OSE Immunotherapeutics 
  492. Ossianix
  493. Oxford Sciences Innovation
  494. Paladin Capital
  495. Pandion Therapeutics 
  496. Panoply Bio
  497. Pascal Biosciences 
  498. Pediatric Brain Tumor Consortium
  499. Penn Medicine
  500. Pennsylvania Industrial Development Authority
  501. Perseus Proteomics
  502. Pfizer
  503. pH Pharma
  504. Phanes Therapeutics
  505. PharmAbcine
  506. PharmaLegacy
  507. Pierre Fabre
  508. Polaris Partners
  509. Potenza Therapeutics
  510. PPF 
  511. Precision Antibody
  512. ProMab Biotechnologies
  513. Protein Alternatives (PROALT)
  514. ProteoGenix
  515. ProtTech
  516. Proxima Ventures
  517. Purdue Pharma
  518. Pure Biologics
  519. PX'Therapeutics
  520. Qianhai Qinzhi Capital
  521. Qiming Venture Partners
  522. QIMR Berghofer Medical Research Institute
  523. QoolAbs
  524. Quan Funds
  525. Quebec Consortium for Drug Discovery (CQDM)
  526. Queen's University
  527. Rapid Novor
  528. RayBiotech
  529. RD-Biotech
  530. Redalpine Venture Partners
  531. Redmile 
  532. Regeneron Pharmaceuticals
  533. Regione Lazio
  534. Resonant Therapeutics
  535. Retrogenix
  536. RevMab Biosciences 
  537. Revolve Biotechnologies
  538. Rezolute
  539. Rhenman & Partners Asset Management
  540. Roche
  541. Rockland Immunochemicals
  542. RubrYc Therapeutics
  543. Rx Biosciences
  544. SAB Biotherapeutics
  545. Sahlgrenska University Hospital
  546. Samsara BioCapital
  547. Samsara Networks
  548. San Diego Biomedical Research Institute
  549. Sanofi
  550. Sanyou Biopharmaceuticals
  551. SARomics Biostructures
  552. Sartorius 
  553. SBH Sciences 
  554. Schroder Adveq
  555. Science Exchange 
  556. Scotia Biologics
  557. Sea Lane Biotechnologies
  558. Seeds Capital
  559. Selecxine
  560. Sensei Biotherapeutics
  561. Sequoia Capital China
  562. Serum Institute of India
  563. Sevion Therapeutics
  564. Shandong Boan Biotechnology 
  565. Shanghai Junshi Biosciences
  566. Shenyang Sunshine Pharmaceuticals
  567. Shenzhen GTJA Investment Group
  568. Shenzhen Hepalink Pharmaceutical
  569. Shenzhen Innovation Capital Investment
  570. Shilps Sciences
  571. Shire
  572. Sichenzia Ross Ference
  573. Sichuan Kelun-Biotech Biopharmaceutical
  574. Siegfried Holding
  575. Silverton Partners
  576. Simcere Pharmaceutical
  577. Simon Fraser University
  578. Single Cell Technology
  579. Sino Biological
  580. Sinobioway
  581. Six.02 Bioservices 
  582. SK Holdings
  583. Sofinnova Partners
  584. Sorrento Therapeutics
  585. SOTIO
  586. South Dakota Equity Partners
  587. SouthernBiotech
  588. Specifica
  589. Sphere Fluidics
  590. Standford University
  591. State Development & Investment
  592. State of Wisconsin Investment Board (SWIB)
  593. Straterx
  594. Summit Partners
  595. Surface Oncology
  596. Surveyor Capital
  597. Sutro Biopharma
  598. Suzhou Bright Scistar Biotechnology (BSBIO)
  599. Suzhou Oriza Holdings
  600. Syd Labs
  601. Symphogen
  602. Synbio Technologies
  603. Syngene
  604. Synthelis
  605. TA Associates
  606. Takeda
  607. Talem Therapeutics
  608. Tanabe Research Laboratories
  609. Tasgen Bio-Tech
  610. Tasly Biopharmaceuticals
  611. TC BioPharm 
  612. Technical University of Denmark
  613. Telix Pharmaceuticals
  614. Temasek Holdings
  615. TeneoBio
  616. TESARO
  617. TetraGenetics
  618. Teva Pharmaceutical Industries
  619. TG Therapeutics
  620. The Antibody Company
  621. The University of Texas MD Anderson Cancer Center
  622. The University of Tokyo
  623. The Wistar Institute
  624. Theraclone Sciences
  625. Theranyx
  626. Thermo Fisher Scientific
  627. Thiel Capital
  628. Third Point Ventures
  629. Third Venture Biopharma
  630. ThromboGenics
  631. Tizona Therapeutics
  632. Tmunity Therapeutics
  633. Torch Biosciences
  634. TRACON Pharmaceuticals
  635. Transcenta Holding
  636. Transgene
  637. TRIANNI
  638. Tri-Institutional Therapeutics Discovery Institute
  639. Tsinghua University
  640. Twist Biopharma
  641. Twist Bioscience
  642. UK Innovation & Science Seed Fund
  643. University College London
  644. University of Navarra
  645. University of Oxford
  646. University of Southampton
  647. University of Surrey
  648. University of Technology Sydney
  649. University of Texas
  650. U-Protein Express
  651. US Department of Defense
  652. Vaccinex
  653. Vall d'Hebron Institute of Oncology
  654. Valneva
  655. Velabs Therapeutics
  656. venBio
  657. VERAXA Biotech
  658. Vertex Holdings 
  659. VI Ventures
  660. Vinnova
  661. Vir Biotechnology
  662. Visterra
  663. Vital Venture Capital
  664. Viva Biotech
  665. Voyager Therapeutics
  666. Washington University School of Medicine
  667. Watson Investments
  668. Wellington Management
  669. Wisconsin Alumni Research Foundation
  670. Woodford Investment Management
  671. Woodford Patient Capital Trust
  672. WuXi AppTec
  673. Wuxi Biologics
  674. XBiotech
  675. xCella Biosciences
  676. X-Chem
  677. Xencor
  678. XOMA
  679. Y- Biologics 
  680. Yale Cancer Center
  681. Yinuoke
  682. YUMAB
  683. Yurogen Biosystems
  684. Zai Lab
  685. Zebra Biologics
  686. Zhejiang Teruisi Pharmaceutical
  687. Zheshang Venture Capital
  688. ZoonBio Biotechnology 
  689. Zumutor Biologics
  690. Zurich Cantonal Bank
  691. Zydus Cadila
  692. Zymeworks

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experienceAccept

Copyright © 2022 Roots Analysis. All Rights Reserved.